Related references
Note: Only part of the references are listed.Fully human CD19-specific chimeric antigen receptors for T-cell therapy
D. Sommermeyer et al.
LEUKEMIA (2017)
Donor CD19 CART cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity
Arnab Ghosh et al.
NATURE MEDICINE (2017)
The Principles of Engineering Immune Cells to Treat Cancer
Wendell A. Lim et al.
CELL (2017)
Clinical pharmacology of CAR-T cells: Linking cellular pharmacodynamics to pharmacokinetics and antitumor effects
M. Norelli et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2016)
Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy
Rebecca Gardner et al.
BLOOD (2016)
CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients
Cameron J. Turtle et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease
Jennifer N. Brudno et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy
Lingfeng Liu et al.
NATURE BIOTECHNOLOGY (2016)
Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells
Cameron J. Turtle et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity
Elad Jacoby et al.
NATURE COMMUNICATIONS (2016)
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
David T. Teachey et al.
CANCER DISCOVERY (2016)
Fine-tuning the CAR spacer improves T-cell potency
Norihiro Watanabe et al.
ONCOIMMUNOLOGY (2016)
Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model
H. Almasbak et al.
GENE THERAPY (2015)
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
James N. Kochenderfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee et al.
LANCET (2015)
Chimeric Antigen Receptors With Mutated IgG4 Fc Spacer Avoid Fc Receptor Binding and Improve T Cell Persistence and Antitumor Efficacy
Mahesh Jonnalagadda et al.
MOLECULAR THERAPY (2015)
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
David L. Porter et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity
Michael Hudecek et al.
CANCER IMMUNOLOGY RESEARCH (2015)
A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy
Brian Philip et al.
BLOOD (2014)
Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15
Yang Xu et al.
BLOOD (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Marco L. Davila et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
Waleed Haso et al.
BLOOD (2013)
IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors
Nicoletta Cieri et al.
BLOOD (2013)
CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma
Monica Casucci et al.
BLOOD (2013)
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study
Conrad Russell Y. Cruz et al.
BLOOD (2013)
Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells
Michael Hudecek et al.
CLINICAL CANCER RESEARCH (2013)
Chimeric Antigen Receptor (CAR)-Specific Monoclonal Antibody to Detect CD19-Specific T Cells in Clinical Trials
Bipulendu Jena et al.
PLOS ONE (2013)
T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
Marcela V. Maus et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Protein L: a novel reagent for the detection of Chimeric Antigen Receptor (CAR) expression by flow cytometry
Zhili Zheng et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells
Cor H. J. Lamers et al.
BLOOD (2011)
IL-7 receptor expression identifies suicide gene-modified allospecific CD8+ T cells capable of self-renewal and differentiation into antileukemia effectors
Attilio Bondanza et al.
BLOOD (2011)
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
Renier J. Brentjens et al.
BLOOD (2011)
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients
Barbara Savoldo et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
Michael Kalos et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?
Margot Zoeller
NATURE REVIEWS CANCER (2011)
The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor
Michael Hudecek et al.
BLOOD (2010)
Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response
A. Hombach et al.
GENE THERAPY (2010)
IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes
Shin Kaneko et al.
BLOOD (2009)
Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study
Fabio Ciceri et al.
LANCET ONCOLOGY (2009)
The role of extracellular spacer regions in the optimal design of chimeric immune receptors - Evaluation of four different scFvs and antigens
RD Guest et al.
JOURNAL OF IMMUNOTHERAPY (2005)
CD44v6: a target for antibody-based cancer therapy
KH Heider et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2004)
Safety of retroviral gene marking with a truncated NGF receptor
C Bonini et al.
NATURE MEDICINE (2003)
Monitoring of engraftment and progression of acute lymphoblastic leukemia in individual NOD/SCID mice
BA Nijmeijer et al.
EXPERIMENTAL HEMATOLOGY (2001)
Share Paper
